Where to from here.., page-57

First 57 Last

Share
Profile

Follow
cocoman

13,814 Posts.

335

22/02/16

09:45

Post #: 17079372
Share

Originally posted by RAllen50 ↑

As @stevenjd said in an earlier post the company flew to 16 cents when it was promise and blue sky. Now it has been re-rated due to revenue (either rightly or wrongly). Most important is that tech globally has been smashed. I saw a table last week that showed every tech stock in the US that IPOd in the last 4 years is below its IPO price except Facebook (and Alibaba is at the same price). Will NOR go below its IPO price? Too early to tell now but to me a SP is irrelevant to a company as they just need to do whatever they need to do to get ahead.

However they seem to have reached a strategy crossroads which may lead to flat results in the future. It seems they have chosen to slow down marketing, leading to fewer direct downloads and pursue free WP-to-WP as the marketing strategy. I think marketing will need to increase in the short term.

You have to assume only a very small percentage of the 3.6m downloads are still using it. Will an iPhone user who downloaded WP in October still have it on their phone? Even if they have it and don't use it, how will NOR reach them?

There would need to be a new marketing effort around free WP-to-WP which means higher cost. So I think cost of acquisition will rise again before it falls. If this leads to new revenues will be one of the tests though management's previous announcements around optimising and testing revenues should lead to a positive result eventually.

Expand

Downloads seem to be happening fine.
It's the engagement and revenue growth that need to be addressed.
This months launch should go a long way to doing that.
I've got talk 360 on my phone too.
They have pop ups all the time on the app icon.
Imagine WP will do the same.

NOR Price at posting: 5.0¢ Sentiment: Buy Disclosure: Held
3 Upvote

0 Great analysis

Reply

Top Stories

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

NEU

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

NYR

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

CHM

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

There are more pages in this discussion • 4 more messages in this thread...

First 57 Last

Add NOR (ASX) to my watchlist

(20min delay)
Last 3.8¢		Change 0.000(0.00%)		Mkt cap ! $18.09M

Open	High	Low	Value	Volume
0.0¢	0.0¢	0.0¢	$0	0

Buyers (Bids)

No.	Vol.	Price($)
2	220000	3.0¢

Sellers (Offers)

Price($)	Vol.	No.
3.7¢	130530	2

View Market Depth

No.	Vol.	Price($)
2	220000	0.030
1	50000	0.029
1	120700	0.028
1	150000	0.027
5	550000	0.026

Price($)	Vol.	No.
0.037	130530	2
0.040	200000	1
0.042	23833	1
0.045	1534501	2
0.046	21759	1

Last trade - 12.31pm 07/10/2024 (20 minute delay)

NOR (ASX) Chart

Day chart unavailable

Where to from here.., page-57

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Where to from here.., page-57

Top Stories

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News